Dispose of the whole syringe in a sharps container
Reports from Q4 2003 to Q1 2024 were analyzed using the OpenVigil 2.1 platform to identify male patients experiencing orgasmic dysfunction, erectile dysfunction, or decreased libido linked to GLP-1 receptor agonists (tirzepatide, semaglutide, dulaglutide, exenatide, lixisenatide, and liraglutide)
These interactions can change how well a medicine works, increase side effects, or cause unexpected reactions
These help with nutrient absorption and satisfaction, but keep portions modest since fats can slow digestion further and potentially increase nausea
Given concerns about muscle mass reduction with GLP-1 RAs, the reviewed paper emphasizes strategies to preserve or restore muscle health